Terms: = Gastric cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS AND Treatment
16 results:
1. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
2. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-sto-0415).
Lorenzen S; Schwarz A; Pauligk C; Goekkurt E; Stocker G; Knorrenschild JR; Illerhaus G; Dechow T; Moehler M; Moulin JC; Pink D; Stahl M; Schaaf M; Goetze TO; Al-Batran SE
BMC Cancer; 2023 Jun; 23(1):561. PubMed ID: 37337155
[TBL] [Abstract] [Full Text] [Related]
3. The impact of the 30-day postoperative complications on the quality of life following gastrectomy for gastric carcinoma: A prospective study.
Jang A; Jeong O
Eur J Surg Oncol; 2023 May; 49(5):983-989. PubMed ID: 36682945
[TBL] [Abstract] [Full Text] [Related]
4. Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-sto-0510.
Högner A; Al-Batran SE; Siveke JT; Lorenz M; Bartels P; Breithaupt K; Malfertheiner P; Homann N; Stein A; Gläser D; Tamm I; Hinke A; Vogel A; Thuss-Patience P;
Int J Cancer; 2022 Mar; 150(6):1007-1017. PubMed ID: 34741530
[TBL] [Abstract] [Full Text] [Related]
5. Hyperactivation of MEK/ERK pathway by Ca
Najar MA; Aravind A; Dagamajalu S; Sidransky D; Ashktorab H; Smoot DT; Gowda H; Prasad TSK; Modi PK; Chatterjee A
Mol Carcinog; 2021 Nov; 60(11):769-783. PubMed ID: 34437731
[TBL] [Abstract] [Full Text] [Related]
6. Health-related quality of life after curative resection for gastric adenocarcinoma.
Grosek J; Zavrtanik H; Tomažič A
World J Gastroenterol; 2021 Apr; 27(16):1816-1827. PubMed ID: 33967559
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of nutrition and quality of life of esophagogastrostomy and the double-tract reconstruction after laparoscopic proximal gastrectomy.
Eom BW; Park JY; Park KB; Yoon HM; Kwon OK; Ryu KW; Kim YW
Medicine (Baltimore); 2021 Apr; 100(15):e25453. PubMed ID: 33847651
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Profiling Associated with Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2)-Mediated Carcinogenesis in gastric cancer.
Najar MA; Modi PK; Ramesh P; Sidransky D; Gowda H; Prasad TSK; Chatterjee A
J Proteome Res; 2021 May; 20(5):2687-2703. PubMed ID: 33844560
[TBL] [Abstract] [Full Text] [Related]
9. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic Esophagogastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO sto 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract] [Full Text] [Related]
10. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients' perspectives.
Libânio D; Braga V; Ferraz S; Castro R; Lage J; Pita I; Ribeiro C; Abreu De Sousa J; Dinis-Ribeiro M; Pimentel-Nunes P
Endoscopy; 2019 Jan; 51(1):30-39. PubMed ID: 29969807
[TBL] [Abstract] [Full Text] [Related]
11. Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.
Korkeila EA; Salminen T; Kallio R; Mikkola M; Auvinen P; Pyrhönen S; Ristamäki R
Support Care Cancer; 2017 Sep; 25(9):2771-2777. PubMed ID: 28424889
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of the EORTC sto-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer.
Woo A; Fu T; Popovic M; Chow E; Cella D; Wong CS; Lam H; Pulenzas N; Lechner B; Vuong S; Ganesh V; Bottomley A
Ann Palliat Med; 2016 Jan; 5(1):13-21. PubMed ID: 26841811
[TBL] [Abstract] [Full Text] [Related]
13. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
14. [Quality of life of patients with locally advanced operated gastric cancer during the period of chemotherapy].
Manikhas GM; Zhukova NV
Vopr Onkol; 2012; 58(5):679-83. PubMed ID: 23600288
[TBL] [Abstract] [Full Text] [Related]
15. Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma.
Kim WS; Park YH; Lee SH; Ryoo BY; Yang SH; Lee SS; Kim MS; Kim K; Park KW; Im DH; Kang JH; Lee J; Ko YH; Ahn YC; Lim DH; Park K; Bang SM
Med Oncol; 2008; 25(4):447-50. PubMed ID: 18431552
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-sto 22, to assess quality of life in patients with gastric cancer.
Blazeby JM; Conroy T; Bottomley A; Vickery C; Arraras J; Sezer O; Moore J; Koller M; Turhal NS; Stuart R; Van Cutsem E; D'haese S; Coens C;
Eur J Cancer; 2004 Oct; 40(15):2260-8. PubMed ID: 15454251
[TBL] [Abstract] [Full Text] [Related]
